List of Excipients in API niraparib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing niraparib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| GlaxoSmithKline LLC | ZEJULA | niraparib | 0173-0909 | CELLULOSE, MICROCRYSTALLINE | 2038-03-27 |
| GlaxoSmithKline LLC | ZEJULA | niraparib | 0173-0909 | CROSPOVIDONE | 2038-03-27 |
| GlaxoSmithKline LLC | ZEJULA | niraparib | 0173-0909 | LACTOSE MONOHYDRATE | 2038-03-27 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for niraparib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
niraparib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
niraparib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
niraparib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 3
niraparib drug variants containing FD&C RED NO. 3
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing FD&C RED NO. 3
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 5
niraparib drug variants containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
niraparib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
niraparib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
niraparib drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERYL MONOCAPRYLOCAPRATE
niraparib drug variants containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing GLYCERYL MONOCAPRYLOCAPRATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
niraparib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
niraparib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
niraparib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
niraparib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE
niraparib drug variants containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing POVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
niraparib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
niraparib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
niraparib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
niraparib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
niraparib drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 0173-0909 |
| >Company | >Ingredient | >NDC |
niraparib drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| GlaxoSmithKline LLC | niraparib | 69656-103 |
| Janssen Biotech Inc | niraparib tosylate monohydrate and abiraterone acetate | 57894-100 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
